1. Introduction {#sec1}
===============

The common liver fluke (*Fasciola hepatica*) causes significant production disease in sheep and cattle worldwide. Control of fasciolosis is based on treatment with flukicides that differ in chemical structure and mode of action, but also in their efficacy against different liver fluke developmental stages ([@bib17]). Triclabendazole (TCBZ) and albendazole (ABZ) are common benzimidazoles used against liver fluke infection ([@bib44]). TCBZ is effective against both adult and juvenile flukes from the age of 2 days, and is the drug of choice for both sheep and cattle, whereas ABZ is effective only against adult flukes (from 12 weeks) ([@bib17]). A demonstrated minimal inhibition concentration of ABZ for all animal products and a short withdrawal period for milk (60 h) ([@bib38]) make ABZ one of the most useful flukicides for dairy cattle.

Resistance of liver flukes to flukicides had not been noted until the first report of TCBZ resistance in Australia in 1995 ([@bib37]). Since then, numerous cases of TCBZ resistance have been reported in Australia ([@bib4]), Europe ([@bib30], [@bib11], [@bib21], [@bib23]) and South America ([@bib36]). The significant increase in reported TCBZ resistance has raised new issues regarding evaluation of flukicide efficacy, diagnostic methods for anthelmintic resistance (AR) and their interpretation. There is no standard recommended protocol for determination of flukicide efficacy/resistance ([@bib16], [@bib18]). Faecal egg count reduction test (FECRT) ([@bib9], [@bib30], [@bib23]), coproantigen reduction test (CRT) ([@bib19], [@bib20], [@bib5]), detection of fluke DNA in faeces by polymerase chain reaction (PCR) ([@bib39]), post-mortem fluke counts ([@bib10]) and histology of flukes exposed *in vivo* ([@bib24]) have all been used for detection of flukicide efficacy in ruminants. In common veterinary practice, a combination of FECRT and CRT seems to be the most promising methods for detection ([@bib22], [@bib31], [@bib4], [@bib13], [@bib33]). For most methods, however, specific thresholds have not yet been determined, which makes interpretation problematic, in particular as drug evaluation can be affected by several other factors such as incorrect dosing, metabolism status of animals treated, inferior quality of the flukicide product used and/or timing of the drug efficacy trial ([@bib15]). Altogether, this makes diagnosis of flukicide resistance complicated.

*In vitro* screening of AR is used for some gastrointestinal nematodes, but its application is limited for liver flukes. No reliable molecular markers for TCBZ resistance have so far been reported ([@bib14], [@bib25]). However, in parallel with larval *in vitro* testing in nematodes, the *Fasciola* egg hatch test (FEHT) has been developed to diagnose susceptibility of *F. hepatica* eggs to ABZ ([@bib1], [@bib6], [@bib40]) and TCBZ ([@bib18], [@bib41]).

In Sweden, control of bovine and ovine fasciolosis has been based solely on ABZ for decades ([@bib31], [@bib35]). Failure of ABZ treatment in sheep has been reported on a single farm in south-western Sweden ([@bib31]). However, the exact reasons for this ABZ failure remain unknown. The presence of juvenile flukes that are unaffected by ABZ makes diagnosis of adulticide efficacy impractical, especially in cases where animals are kept outdoors all year round. Implementation of FEHT, which is independent of drug trial data, metabolism and re-infection status of animals tested, would improve diagnosis of resistance to adulticide anthelmintics such as ABZ. The aim of the present study was thus to evaluate ABZ and TCBZ efficacy in sheep naturally infected with *F*. *hepatica* using a combination of faecal egg counts (FEC) and coproantigen reduction, supported by FEHT. In addition, the effect of drug application timing was assessed.

2. Material and methods {#sec2}
=======================

2.1. Animals {#sec2.1}
------------

Two flocks of Gotlandic Pelt sheep on islands of south-western Sweden with a long history of fasciolosis were selected for the study. Both farms are located off the west coast, north of Gothenburg, in a highly liver fluke abundant area ([@bib34]). One farm (farm A) is located on the island of Orust and the other (farm B) on the neighbouring island of Tjörn. The sheep flocks consist of 70 and 150 ewes on farm A and B, respectively. The distance between the farms is approx. 30 km, so the climatic conditions are almost identical at both locations. To control liver fluke, albendazole (ABZ) or/and triclabendazole (TCBZ) have been applied orally in both sheep flocks for a period of 10 years and 2 years, respectively. Animals were last treated (with ABZ) 12 months before the study. In order to select animals with patent liver fluke infection, 50% of the ewes in each flock were sampled in October 2014. In this pre-screening test, faecal samples were collected and examined for the presence of *F*. *hepatica* coproantigen as described below. Based on the results of pre-screening, coproantigen-positive ewes were randomly divided into groups of 6--8 animals.

2.2. Deworming and evaluation of drug efficacy {#sec2.2}
----------------------------------------------

On both farms, two groups of 6--8 ewes were treated with ABZ or TCBZ in January (9 and 11 weeks after housing on farm A and B, respectively). To compare the efficacy of ABZ between autumn and winter deworming, other two groups of ewes were treated with ABZ or TCBZ on farm A in November (4 weeks after housing). However, November deworming was not feasible on Farm B, as the ewes were already pregnant at that time and the use of ABZ is contraindicated in such cases. All animals were weighed and treated orally with a commercial formulation of either ABZ (Valbazen^®^, Pfizer) at a dose of 7.6 mg per kg bodyweight or TCBZ (Triclafas^®^ Oral Drench, Norbrook) at a dose of 10 mg per kg bodyweight. The drug was administered in 50 ml syringes with 0.2 ml accuracy by a licensed veterinary surgeon (employed by Farm & Animal Health, Sweden) as part of routine deworming. No ethical permission was required according to the Animal Welfare Act 2009/021. All drugs were stored in a cool, dry place until use. The animals were kept indoors during the entire study.

2.3. Faecal egg counts and coproantigen ELISA {#sec2.3}
---------------------------------------------

Faecal samples were collected on days 0, 7 and 21 post-treatment, based on previous studies ([@bib30], [@bib4], [@bib23]). The samples were labelled with the animal ID on ear tags and immediately sent by mail to our laboratory in Uppsala. The samples were stored at 4 °C during delivery and storage and processed immediately after arrival. The maximum interval between sampling on the farm and sample processing in the laboratory was 48 h. The FEC were conducted by the sedimentation method on 3 g of faeces as described by [@bib33]. Coproantigen in faecal samples was determined using a commercial kit BIO-X ELISA (BIO K 201, BIO-X Diagnostics, Belgium) according to the manufacturer's protocol, where coproantigen levels are expressed as a percentage of positivity of optical density of sample versus optical density of a positive reference sample. The cut-off value for cELISA was optimised by previous examination of truly *F*. *hepatica*-positive and -negative sheep faecal samples ([@bib5], [@bib33]). Reference positive sheep faecal samples originated from previous studies ([@bib31], [@bib32]) where infection status was confirmed by coproscopy, serology and liver fluke burden. Negative sheep samples came from *F*. *hepatica*-free herds in Uppsala.

2.4. *In vitro Fasciola* egg hatch test {#sec2.4}
---------------------------------------

Sensitivity of the two ovine *F*. *hepatica* isolates to ABZ was assessed by *in vitro* FEHT. The principles of FEHT have been described elsewhere ([@bib1], [@bib18], [@bib6]), although our protocol was somewhat modified as described below. Eggs were obtained from pooled faecal samples before treatment in both herds (farms A and B). An additional cattle *F*. *hepatica* isolate was obtained from adult worms collected at a local abattoir (Varekils Slakteri, Lundby) from the liver of beef cattle from farm C, located approximately 5 km from sheep farm B.

The FEHT was carried out in 24-well, flat-bottomed plastic plates (Nunc, Sigma-Aldrich, Sweden). Albendazole powder (Sigma-Aldrich, Sweden; product ID A4673) was dissolved in maximum 0.5% dimethyl sulphoxide (DMSO) (Sigma Aldrich, Sweden, product ID 472301). This maximum concentration of DMSO had no effect on egg development in our preliminary tests ([@bib3]) or in a previous study ([@bib18]). Fluke eggs were exposed to ABZ at a final concentration of 0.02, 0.1, 0.5, 2.5, 12.5 nmol/ml and 0.5% DMSO only (negative control) for 12 h at 25 °C. Each concentration was tested in four replicates containing approximately 100 eggs per well. After exposure, the eggs were washed three times in tap water and then incubated in 24-well plates in 2 ml tap water for 14 days at 25 °C in the dark. After incubation, miracidial hatching was stimulated by exposure to intensive light for 12 h. Hatching was terminated by adding of 0.1 ml Lugol's iodine solution to each well 4 h after exposure to light. Hatched and unhatched, including dead eggs and eggs with developed miracidia were counted under an inverted microscope at 40x magnification. Ovicidal activity of ABZ was calculated according to the formula, below: Ovicidal activity (%) = (% of eggs hatched in negative control - % eggs hatched after drug exposure/% of eggs hatched in negative control)\*100 ([@bib1], [@bib6]).

2.5. Statistical analysis {#sec2.5}
-------------------------

Faecal egg count was calculated by two independent methods. First, FEC reduction was expressed as a comparison of arithmetic means between pre-treatment and post-treatment levels with 95% confidence limit, as recommended by The World Association for the Advancement of Veterinary Parasitology (WAAVP) ([@bib7]). In the second method, the percentage of FEC reduction was obtained using the online Bayesian hierarchical modelling platform "eggCounts" <http://www.math.uzh.ch/as/index.php?id=254> ([@bib46]).

The cut-off value for coproantigen ELISA was calculated using receiver operating characteristic (ROC) analysis. Treatment effect between drugs and also between deworming periods in each herd was assessed by two-way ANOVA, followed by Bonferroni post-tests with significance *P* \< 0.05. One-way analysis of variance (ANOVA) was applied to evaluate differences between pre-treatment and post-treatment FEC and coproantigen levels in each group. In FEHT, ABZ concentration was plotted against percentage of ovicidal activity after probit transformation. A non-linear regression model was then built to fit dose-response data from FEHT. The EC~50~ values, 95% confidence intervals and R^2^ values were calculated for each *F*. *hepatica* isolate. All analyses were conducted using Graph Pad Prism 5.02 (GraphPad Software, USA).

3. Results {#sec3}
==========

The cut-off value for coproantigen ELISA based on 40 positive and 40 negative control samples was 1.6% positivity. TCBZ was highly efficient (FECR 97--100%) in both flocks, irrespective of deworming period, as documented by FEC and coproantigen levels ([Fig. 1](#fig1){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}). On farm A, ABZ efficacy based on FEC (21 days post-treatment) was slightly lower for November treatment (92%) than for January treatment (99%), but this difference was not significant. FECR values were lower on day 7 in both ABZ and TCBZ groups and raised to 99% on day 21 post-treatment ([Table 2](#tbl2){ref-type="table"}) on farm A likely due to continuous release of eggs remaining in bile ducts and gall bladder. Coproantigen efficacy of ABZ was similar in both the November and January treatments on day 21 post-treatment. In addition, no significant difference in FEC and coproantigen (*P* \> 0.05) was observed between November and January treatment for the TCBZ and ABZ groups on farm A. On farm B, both coproantigen and FEC data showed low efficacy in the ABZ group, where 50% of animals remained coproantigen-positive 21 days post-treatment ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Fig. 1](#fig1){ref-type="fig"}).

The FEHT data showed an obvious difference in sensitivity to ABZ between *F*. *hepatica* eggs isolated from animals on farms A and B. At a concentration of 2.5 nmol/ml, the ovicidal activity of ABZ was 100% for the ovine isolate from farm A but only 54% for the farm B isolate. Furthermore, the bovine isolate from farm C displayed similar poor ovicidal activity to the ovine isolate from farm B. The EC~50~ values for the ovine and bovine isolates from farms B and C were approximately 10-fold higher than that obtained for the ovine isolate from farm A. Data from FEHT, including EC~50~ and R^2^ values, are summarised in [Table 3](#tbl3){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}.

4. Discussion {#sec4}
=============

It has been suggested that ABZ resistance may be present in *F*. *hepatica* in Swedish sheep flocks in response to long term use of lower doses (e.g. 5 mg/kg bodyweight) than the recommended (7.5 mg/kg) in most countries ([@bib31]). However, until now, convincing evidence for this claim has been lacking. In the present study, both reduced efficacy and decreased sensitivity of fluke eggs to ABZ was confirmed in a *F*. *hepatica* population from one sheep flock on the Swedish west coast using two independent coprological methods and an *in vitro* egg hatch test, respectively. ABZ resistance is difficult to prove in the field due to the potential presence of juvenile flukes, which are tolerant to the drug and thus unaffected by treatment. However, as the results of the *in vitro* test confirmed the outcome from the field trial, the observed ABZ treatment failure was most likely associated with resistance.

When flukicides are applied in general practice, diagnosis of flukicide efficacy/resistance can be compromised by several factors. For example, underdosing, poor quality of anthelmintic product, age of product, changes in drug metabolism within animals, inappropriate diagnostic tests may often be misdiagnosed as AR ([@bib15], [@bib44]). In addition, in the case of adulticide drugs, misinterpretation related to the development of juvenile flukes surviving treatment must always be considered ([@bib8]). The WAAVP guidelines cite dose and slaughter trials as the only definitive method for detection of AR ([@bib8]). However, this involves costly and lengthy experimental infection of cultured snails and maintenance of experimental animals. Implementation of FEHT in diagnosing flukicide resistance provides a new approach that is independent of drug efficacy trials in treated animals. In the present study, we observed ABZ failure on farm B, as documented by FEC (67% efficacy) and coproantigen (32% efficacy) ([Table 2](#tbl2){ref-type="table"}). However, it should be emphasised that ABZ was applied in the beginning of January, exactly 9 weeks after housing on this farm. Thus, presence of juvenile flukes cannot be completely excluded on farm B and a decreasing trend in efficacy of both FEC and coproantigen ([Table 2](#tbl2){ref-type="table"}) could hypothetically indicate maturation of juvenile flukes surviving treatment. Furthermore, both initial FEC and coproantigen levels were very low, suggesting a modest fluke burden. In nematodes, low initial FEC before treatment decreases the reliability of FECRT ([@bib7]). It can be assumed that a similar pattern applies for FEC and coproantigen in *F*. *hepatica*. Thus, decisions about the resistance status of the ovine *F*. *hepatica* population on farm B cannot be completely conclusive based only on the FECR and cELISA results. On the other hand, significant differences in ovicidal activity in FEHT between the ovine isolates studied here confirmed that the isolate from farm B possessed significantly lower susceptibility to ABZ than the isolate from farm A. Obvious differences between the isolates studied were also observed in terms of ABZ efficacy based on FEC and cELISA. Thus, the *F*. *hepatica* isolate from farm B is most likely resistant to ABZ.

The majority of studies dealing with flukicide resistance focus on the most effective drug, TCBZ, which is effective against both juvenile and adult flukes in livestock (see review by [@bib16]). In contrast, diagnosis of ABZ susceptibility/resistance has been neglected. So far, the only experimentally confirmed published account of a "dose and slaughter trial" ABZ-resistant fluke population is in Argentina ([@bib42]). Field-based cases of ABZ resistance have been reported in Spain and Egypt ([@bib2], [@bib39], [@bib43], [@bib28]). In addition, the Argentinian CEDIVE isolate ([@bib42]) and the Spanish Santillán de la Vega isolate ([@bib39]) have been confirmed as ABZ-resistant by *in vitro* FEHT ([@bib6], [@bib40]). However, reports of field-documented flukicide resistance that subsequently turn out as incorrect by further investigation have also been presented ([@bib16]). This shows that combining field drug trials with *in vitro* FEHT is necessary for correct diagnosis of ABZ resistance. Interestingly, ABZ is effective in TCBZ-resistant populations ([@bib10]) despite both actives being benzimidazole derivates. At the same time sheep with ABZ-resistant flukes have been successfully treated with TCBZ ([@bib39], [@bib42]), as also documented in our study. This clearly supports the theory that the molecular mechanisms of ABZ and TCBZ resistance differ.

Underdosing, long-term use of compounds with the same mode of action and high frequency of treatment are key factors in development of AR in gastrointestinal nematodes ([@bib27]). In Sweden, ABZ has been used against liver flukes for decades, as until recently it was the only licensed flukicide. However, the dose used for deworming is 1.5-fold lower than recommended in several other countries ([@bib31]). Therefore, the recommended dose of Valbazen (ABZ) in Sweden was recently increased to 7.6 mg/kg of ABZ, i.e. the dose that was used in this study. Repeated underdosing and long-term use of ABZ only might explain the emergence of ABZ resistance in Sweden.

Albendazole acts only against mature flukes older than 12 weeks post-infection ([@bib26], [@bib10]). Thus, ABZ is not usually effective when applied during or immediately after the grazing season, due to the presence of immature flukes ([@bib29]). Surprisingly, the final effect of drug application timing between November and January deworming in this study did not differ for either drug on farm A. Although FECR for ABZ was slightly lower in November, coproantigen values did not differ from the January results. In the autumn treatment, the drugs were applied 4 weeks after housing. Although immature flukes could be expected in ewes at that time of the year, ABZ efficacy was similar to that observed at the January treatment suggesting that all flukes were mature already in November. In Sweden, sheep are infected at the earliest in May--June with metacercarial cysts shed from overwintering snails, but also in July--August as a result of summer infection ([@bib32]). Thus, sheep on farm A were most likely infected in early summer and, from a practical point of view, our results indicate that treatment with ABZ could be applied from November onwards during the housing period.

The FEHT is a relatively new *in vitro* method for testing the ovicidal activity of flukicides. In this study, we used short-term exposure (12 h) to ABZ according to [@bib1], as this time corresponds to *in vivo* exposure. In other studies ([@bib18], [@bib40], [@bib41]), *Fasciola* eggs were incubated for 14 days until hatching of miracidia. Using DMSO at a final concentration of 0.5% in our protocol did not affect the viability of the eggs. This concentration was suggested by our preliminary testing ([@bib3]), and by a previous *in vitro* study with TCBZ ([@bib18]). Higher concentrations of DMSO seem to have an ovicidal effect in *F*. *hepatica*.

In FEHT optimisation, the highest variation in the ovicidal activity of ABZ was observed in the range 0.1--2.5 nmol/ml ([@bib3]). Similarly, [@bib6] showed that 0.5 nmol/ml is the threshold ABZ concentration to discriminate between ABZ-resistant and ABZ-susceptible *F*. *hepatica* isolates. At this ABZ concentration, ovicidal efficacy of ≤40% or ≥70% indicates resistance and susceptibility to ABZ, respectively. We observed ovicidal efficacy of 94% (farm A), 22% (farm B) and 37% (farm C), suggesting that the ovine and bovine isolates from two nearby farms (B and C, respectively) were most likely ABZ-resistant. In nematodes, susceptibility/resistance status of isolates in *in vitro* tests is compared strictly on a dose-response basis using linear or non-linear regression and comparison of data against a standard resistant reference strain ([@bib45], [@bib12]). In this study, *F*. *hepatica* isolates were exposed to ABZ concentrations in the range 0.02--12.5 nmol/ml and there was a noticeable dose-response effect. High R^2^ values (R^2^ \> 0.9 for all three isolates) in non-linear regression showed that the model fitted our data. Since no standard ABZ-resistant reference *F*. *hepatica* isolate is available, interpretation of FEHT data is difficult. However, the EC~50~ value of the ovine isolate from farm A was 10-fold lower than that obtained for the ovine (farm B) and bovine (farm C) isolates from Tjörn, suggesting significant differences in their susceptibility to ABZ.

5. Conclusions {#sec5}
==============

Albendazole is a commonly used flukicide around the world. Unlike in many other European countries it has long been used as drug of first choice against liver flukes in sheep in Sweden. The first confirmed case of ABZ resistance in sheep in Sweden is reported in this study. This finding should be taken into account in future planning of control strategies against fasciolosis. Combined testing with FEC, cELISA and FEHT appears to be efficient in diagnosis of ABZ resistance in the field. Despite high efficacy of ABZ at November deworming observed in the study, we recommend using ABZ at least 12 weeks after housing in sheep, since time of fluke infection may vary between locations. In addition, ABZ is contraindicated in the first 30 days of gestation.
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###### 

Summary of faecal egg counts (FEC) expressed as eggs per gram faeces (EPG) and coproantigen level (% positivity) measured on sheep farms on farm A (Orust) and farm B (Tjörn).

                                                                                Farm A                                Farm B                                                                                                                                                                           
  ----------------------------------------------------------------------------- ------------------------------------- ------------- ------------- ------------- ----------------------------------------- ------------- --------------- -------------- ----------- ----------- ----------- ----------- -----------
  ABZ                                                                           Mean FEC (EPG) ± standard deviation   n.a.          56.0 ± 44.1   0.7 ± 1.2     4.6 ± 10.5                                n.a.          135.5 ± 153.0   60.3 ± 131.4   1.8 ± 4.5   n.a.        3.9 ± 4.6   1.1 ± 2.2   1.2 ± 1.4
  Number of F. hepatica egg shedding animals (number of animals in the group)   n.a.                                  6 (6)         3 (6)         3 (6)         n.a.                                      8 (8)         3 (8)           3 (8)          n.a.        8 (8)       4 (8)       5 (8)       
  Mean % coproantigen positivity ± standard deviation                           41.9 ± 34.9                           29.1 ± 27.8   1.0 ± 1.2     0.8 ± 0.6     29.0 ± 25.8                               31.2 ± 30.2   1.5 ± 3.6       0.6 ± 0.8      8.1 ± 9.0   5.3 ± 5.0   1.3 ± 1.2   3.6 ± 4.3   
  Number of coproantigen positive animals (number of animals in the group)      6 (6)                                 6 (6)         2 (6)         0 (6)         6 (8)[a](#tbl1fna){ref-type="table-fn"}   8 (8)         1 (8)           1 (8)          8 (8)       6 (8)       3 (8)       4 (8)       
  TCBZ                                                                          Mean FEC (EPG) ± standard deviation   n.a.          72.8 ± 71.2   13.4 ± 30.8   0.1 ± 0.1                                 n.a.          62.9 ± 76.7     9.6 ± 14.3     0.4 ± 0.3   n.a.        3.1 ± 2.1   0.0         0.0
  Number of F. hepatica egg shedding animals (number of animals in the group)   n.a.                                  8 (8)         5 (8)         2 (8)         n.a.                                      7 (7)         3 (7)           1 (7)          n.a.        7 (7)       0 (7)       0 (7)       
  Mean % coproantigen positivity ± standard deviation                           36.5 ± 27.7                           24.7 ± 20.8   0.3 ± 0.2     0.5 ± 0.3     37.8 ± 25.6                               25.5 ± 25.7   0.1 ± 0.8       0.3 ± 0.4      7.8 ± 7.8   8.2 ± 7.6   0.1 ± 0.5   0.3 ± 0.3   
  Number of coproantigen positive animals (number of animals in the group)      8 (8)                                 8 (8)         0 (8)         0 (8)         6 (7)[a](#tbl1fna){ref-type="table-fn"}   7 (7)         0 (7)           0 (7)          7 (7)       6 (7)       0 (7)       0 (7)       

Abbreviations:ABZ = albendazole, TCBZ = triclabendazole.

On farm A in January, 2 and 1 sheep were slaughtered in period between pre-screening (Day -75) and Day 0 in ABZ and TCBZ group, respectively. These slaughtered animals were replaced with 3 other coproantigen and *Fasciola hepatica* egg positive sheep on Day 0. Data for these 3 slaughtered sheep were not included on Day -75.

###### 

Efficacy of albendazole and triclabendazole against liver flukes based on faecal egg counts (FEC) and coproantigen ELISA tests on faecal samples obtained 7 and 21 days post-treatment on sheep farms on Orust (farm A) and Tjörn (farm B).

                                                          Farm A                                                  Farm B                                                                     
  ------------------------------------------------------- ------------------------------------------------------- --------------- ------------- -------------- -------------- -------------- ------------
  Albendazole                                             FECR in %, (95% CI)[a](#tbl2fna){ref-type="table-fn"}   99 (94--100)    92 (35--99)   56 (0--93)     99 (90--100)   71 (0--95)     69 (0--91)
  FECR in %, (95% CI)[b](#tbl2fnb){ref-type="table-fn"}   99 (97--100)                                            92 (88--94)     56 (51--60)   99 (98--99)    73 (45--88)    67 (35--84)    
  Coproantigen reduction in %                             97                                                      97              95            98             76             32             
  Triclabendazole                                         FECR in %, (95% CI)[a](#tbl2fna){ref-type="table-fn"}   82 (0--97)      100           85 (30--97)    99 (94--100)   100            100
  FECR in %, (95% CI)[b](#tbl2fnb){ref-type="table-fn"}   82 (77--85)                                             100 (99--100)   85 (80--88)   99 (98--100)   97 (82--100)   97 (83--100)   
  Coproantigen reduction in %                             99                                                      98              100           99             99             97             

Abbreviations: 95% CI = 95% confidence interval, FECR = faecal egg count reduction.

Faecal egg count reduction calculated according to [@bib7].

Faecal egg count reduction calculated according to [@bib46].

###### 

Ovicidal efficacy determined by *in vitro Fasciola* egg hatch test (FEHT) of albendazole (ABZ) at concentrations 0.02, 0.1, 0.5, 2.5, and 12.5 nmol/ml against *F*. *hepatica* eggs of two ovine isolates (farm A and B) and one bovine isolate (farm C).

  ABZ (nmol/ml)      Ovicidal efficacy                    
  ------------------ ------------------- ---------------- ----------------
  12.5               100                 100              100
  2.5                100                 54.5             74.2
  0.5                94.4                37.5             22.2
  0.1                57.2                20.9             6.1
  0.02               3.6                 16.4             5.8
  EC~50~             0.087               0.947            1.171
  95% CI of EC~50~   0.078 to 0.098      0.207 to 4.334   0.822 to 1.667
  R^2^               0.998               0.901            0.993

Abbreviations:; EC~50~ = effective concentration for 50% inhibition; R^2^ = coefficient in regression analysis.
